The latest Investing Matters Podcast episode featuring Jeremy Skillington, CEO of Poolbeg Pharma has just been released. Listen here.

Less Ads, More Data, More Tools Register for FREE

Pin to quick picksTPG.L Regulatory News (TPG)

  • There is currently no data for TPG

Watchlists are a member only feature

Login to your account

Alerts are a premium feature

Login to your account

Business Update

31 Oct 2022 07:00

RNS Number : 5785E
TP Group PLC
31 October 2022
 

This announcement contains inside information 

31 October 2022

 

TP Group plc

("TP Group", "Group" or "Company")

 

Business Update

 

Following the investment by Science Group plc and the subsequent Board changes, the strategy for TP Group was set out on 1 November 2021. The Board has regularly updated shareholders on the execution of that strategy, including the restructuring of the Group and the substantial challenges associated with the legacy contracts in the Maritime Division which have been well documented in the TP Group 2021 Annual Report and the 2022 Interim Results together with other announcements made over the past year. The Board now provides a further update to shareholders.

 

Maritime Division Contracts

 

The TPG Maritime division provides products and services associated with air handling systems for submarines. This is a specialist defence industry business with a small but international client base. In 2021, the TPG Maritime Division ("TPGM") had seven major customers, defined as revenue in excess of £0.5m in the year. Of those major clients, five contracts required priority renegotiation or termination. A summary of the current status of these contracts is as follows :

 

Contract A (UK Customer) : The overspend on this large, fixed price contract only became apparent early in 2022, resulting in material provisions and prior year adjustments as previously reported. Continuing with this very onerous contract in its original form was not financially viable for TPGM, placing the business at serious risk of insolvency. As a result of a protracted negotiation, agreement has now been reached with the customer such that the contract has been restructured as a Qualifying Sub-Contract, mitigating future exposure. While the margin associated with this contract will be significantly lower than had been originally anticipated and the terms remain sub-optimal, the Board concluded that it is in the best interests of all stakeholders to accept this compromise in relation to the current supply obligations but that any future product supply would require alternative contract arrangements.

 

Contract B (European Customer) : An agreement has been reached to settle the legacy liabilities and the customer wishes TPGM to complete the supply programme on the revised terms. The settlement includes a potential payment by TPGM of up to £0.4 million which may be reduced subject to future performance.

 

Contract C (European Customer) and Contract D (Asian Customer) : Progress has been made with these clients, resulting in a reasonable probability, but no certainty, of a satisfactory compromise. Negotiations are continuing.

 

Contract E (Hydrogen-powered train project) : TPGM had been acting as the reseller intermediary between a US supplier and a UK client in relation to this diversification. TPGM has agreed terms in principle with the other parties to exit this arrangement.

 

Of the remaining customers, it should be noted that a large UK consumables support contract is subject to re-tender in the next year. This contract accounted for approximately one third of TPGM revenue in 2021 and a greater proportion in the first half of 2022, although the gross margin is low. TPGM anticipates bidding to renew this contract but there can be no certainty as to the outcome.

 

As part of the contract renegotiations, the Board has removed or terminated parent company guarantees previously provided by TP Group plc to TPGM. Such guarantees potentially undermine the principle of limited liability of the subsidiary, exposing the Group to the TPGM liabilities and potentially inhibiting the Board's options.

 

TPG Services Division

 

The Services division has continued to perform satisfactorily with a continued focus on improving contract margins. The integration of Osprey, initiated over the summer, is progressing well with increasing alignment of strategic, operational and financial objectives.

 

Opportunities for collaboration between TPG Services and the Science Group R&D Division have been identified and are being developed by the respective operating management teams. Such cooperation should enable these businesses to offer new service capabilities into defence industry clients.

 

Westek

 

Following the disposal of Northstar (April 2022) and Sapienza (July 2022), negotiations regarding the potential disposal of Westek are continuing with a preferred buyer. The valuation is modest and there is no certainty that a transaction will be completed. An alternative strategy to retain Westek within the Group will be implemented if a transaction is not concluded.

 

Group Financing

 

The current aggregate facilities (HSBC and Science Group) total £11 million of which approximately £7.0 million is currently drawn, including the bank facility which remains fully drawn at approximately £6 million. In recent months, the Group has partially drawn on the Science Group standby facility in order to fund working capital requirements. Current cash flow forecasts indicate that the Science Group facility may continue to be required in the coming months. 

 

The current bank facility and the Science Group standby facility expire in September 2023. The Board does not anticipate either facility will be renewed and therefore alternative funding arrangements will need to be in place by the end of the year in order for the Group to satisfy the requirements in relation to financial reporting as a going concern. While the Board has initiated discussions to explore potential alternative financing sources, it is apparent that a pre-condition to any refinancing is that the legacy TPGM contracts are satisfactorily resolved. Furthermore, in the current UK economic environment, there is no certainty that new debt facilities will be available on terms which are acceptable or can be agreed in a timely manner.

 

The Board has not ruled out the possibility of an equity fund raise, but it recognises that at the current share price such a refinancing would likely result in a significant dilution of existing shareholders who did not or were unable to participate.

 

Summary

 

The onerous nature of the legacy TPGM contracts became apparent in late 2021 and early 2022. The materiality and seriousness of the situation progressively escalated during the subsequent months. Ultimately, these contracts placed the future of the Maritime subsidiary, and potentially the entire Group, in jeopardy. The new management team installed at TPGM, led by a senior manager seconded from Science Group, has brought a new rigour and discipline to the division enabling the contracts to be renegotiated, a serious financial solvency crisis to be averted and implementation of necessary operational and commercial improvements.

 

To remain as an independent company, the capital structure of the Group needs to be addressed. It is not certain that any refinancing can be completed on terms which would be acceptable to the Board or TP Group shareholders.

 

 

Recommended Offer by Science Group plc

 

While the TPGM contract negotiations are ongoing, sufficient progress has been made which, together with the disposals of the non-core operations, has enabled the Independent Directors and Science Group plc to agree terms for a recommended offer for TP Group plc ("Offer") at a significant premium to the current share price. The Independent Directors of TP Group strongly recommend that shareholders accept the Offer, which is anticipated to be implemented by a Scheme of Arrangement. Details of the Offer are set out in a separate announcement released today.

 

Contact:

TP Group plc

Tel: 01753 285802

Martyn Ratcliffe, Executive Chairman

Derren Stroud, Chief Financial Officer

www.tpgroupglobal.com

Cenkos Securities plc

Tel: 020 7397 8980

Stephen Keys / Mark Connelly / Callum Davidson

www.cenkos.com

 

This information is provided by RNS, the news service of the London Stock Exchange. RNS is approved by the Financial Conduct Authority to act as a Primary Information Provider in the United Kingdom. Terms and conditions relating to the use and distribution of this information may apply. For further information, please contact rns@lseg.com or visit www.rns.com.RNS may use your IP address to confirm compliance with the terms and conditions, to analyse how you engage with the information contained in this communication, and to share such analysis on an anonymised basis with others as part of our commercial services. For further information about how RNS and the London Stock Exchange use the personal data you provide us, please see our Privacy Policy.
 
END
 
 
UPDGZMFGZGLGZZZ
Date   Source Headline
27th Jan 20237:00 amRNSCancellation - TP Group Plc
26th Jan 202310:16 amRNSForm 8.5 (EPT/NON-RI) - TP Group PLC
26th Jan 202310:05 amRNSScheme Effective
26th Jan 20237:30 amRNSSuspension - TP Group Plc
25th Jan 20239:20 amRNSForm 8.5 (EPT/NON-RI)
24th Jan 20232:21 pmRNSCourt Sanction of Scheme of Arrangement
24th Jan 20238:55 amRNSForm 8.5 (EPT/NON-RI)
23rd Jan 20235:30 pmRNSTP Group
20th Jan 20239:05 amRNSForm 8.5 (EPT/NON-RI)
19th Jan 20238:26 amRNSForm 8.5 (EPT/NON-RI)
18th Jan 202312:11 pmRNSForm 8.3 - TP Group plc
18th Jan 202312:09 pmRNSForm 8.3 - TP Group plc
18th Jan 20238:37 amRNSForm 8.5 (EPT/NON-RI)
17th Jan 20238:45 amRNSForm 8.5 (EPT/NON-RI)
16th Jan 202312:53 pmRNSForm 8.3 - TP Group plc
16th Jan 20238:40 amRNSForm 8.5 (EPT/NON-RI)
13th Jan 20239:03 amRNSForm 8.5 (EPT/NON-RI)
12th Jan 20238:46 amRNSForm 8.5 (EPT/NON-RI)
11th Jan 20239:38 amRNSForm 8.5 (EPT/NON-RI)
10th Jan 20239:11 amRNSForm 8.5 (EPT/NON-RI)
9th Jan 20238:36 amRNSForm 8.5 (EPT/NON-RI)
9th Jan 20237:00 amRNSRegulatory Clearance & Scheme Timetable Update
6th Jan 20238:25 amRNSForm 8.5 (EPT/NON-RI)
5th Jan 20238:17 amRNSForm 8.5 (EPT/NON-RI)
4th Jan 20239:14 amRNSForm 8.5 (EPT/NON-RI) - TP Group PLC
29th Dec 20223:04 pmRNSSale of Westek Technology Ltd.
29th Dec 20228:44 amRNSForm 8.5 (EPT/NON-RI)
22nd Dec 20228:56 amRNSForm 8.5 (EPT/NON-RI)
21st Dec 202212:22 pmRNSHolding(s) in Company
21st Dec 20229:22 amRNSForm 8.5 (EPT/NON-RI)
20th Dec 202211:10 amRNSForm 8.5 (EPT/NON-RI)
19th Dec 202210:23 amRNSForm 8.5 (EPT/NON-RI)
19th Dec 20229:29 amRNSForm 8.3 - TP Group PLC
15th Dec 20228:58 amRNSForm 8.5 (EPT/NON-RI)
14th Dec 20223:33 pmRNSResult of Court Meeting & General Meeting
14th Dec 202210:26 amRNSForm 8.5 (EPT/NON-RI)
8th Dec 20228:34 amRNSForm 8.5 (EPT/NON-RI)
7th Dec 202210:46 amRNSForm 8.5 (EPT/NON-RI)
6th Dec 20228:54 amRNSForm 8.5 (EPT/NON-RI)
2nd Dec 202210:02 amRNSForm 8.5 (EPT/NON-RI)
1st Dec 20229:55 amRNSForm 8.5 (EPT/NON-RI)
1st Dec 20228:15 amRNSForm 8.3 -TP Group PLC
30th Nov 20228:54 amRNSForm 8.5 (EPT/NON-RI)
29th Nov 20228:14 amRNSForm 8.3 - TP GROUP PLC
28th Nov 20228:22 amRNSForm 8.3 - TP Group PLC
24th Nov 202210:39 amRNSForm 8.5 (EPT/NON-RI)
24th Nov 20228:28 amRNSForm 8.3 - TP GROUP PLC
23rd Nov 20228:48 amRNSForm 8.3 - TP GROUP PLC
22nd Nov 20229:45 amRNSForm 8.5 (EPT/NON-RI)
22nd Nov 20228:26 amRNSForm 8.3 - TP GROUP PLC

Due to London Stock Exchange licensing terms, we stipulate that you must be a private investor. We apologise for the inconvenience.

To access our Live RNS you must confirm you are a private investor by using the button below.

Login to your account

Don't have an account? Click here to register.

Quickpicks are a member only feature

Login to your account

Don't have an account? Click here to register.